 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon's president and chief financial officer, Tom Garner...

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two...

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX  Get Free Report) was the recipient of a significant drop in short interest in February. As of February 29th, there was short interest totalling...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Sees Large Decrease in Short Interest

KWB Wealth bought a new position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX  Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and...

KWB Wealth Invests $62,000 in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX  Get Free Report) fell 6.8% on Tuesday . The stock traded as low as $2.51 and last traded at $2.62. 3,249,144 shares were traded during mid-day...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Down 6.8%

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX  Get Free Report)s stock price gapped up before the market opened on Monday . The stock had previously closed at $2.17, but opened at $2.32...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up to $2.17

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX  Get Free Report) was the target of some unusual options trading activity on Monday. Stock investors bought 7,172 call options on the company. This...

Investors Buy High Volume of Lexicon Pharmaceuticals Call Options (NASDAQ:LXRX)

THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial...

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX  Get Free Report) shares were down 6.8% during trading on Tuesday . The stock traded as low as $2.51 and last traded at $2.62. Approximately...

Commercial launch of INPEFA (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase...

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Volume (M)	2.99M
52-Wk High	$3.79
52-Wk Low	$0.92

LXRX Lexicon Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals